FOXR2 stabilizes MYCN protein and identifies non-MYCN-amplified neuroblastoma patients with unfavorable outcome

Clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to fatality. Hence, understanding the mechanisms that cause tumor progression is crucial for the treatment of patients. In this study, we show that FOXR2 activation identifies a subset of neuroblastoma tumors wi...

Full description

Bibliographic Details

Main Authors:	Schmitt-Hoffner, Felix (Author) , van Rijn, Sjoerd (Author) , Toprak, Umut (Author) , Mauermann, Monika (Author) , Rosemann, Felix (Author) , Heit-Mondrzyk, Anke Claudia (Author) , Hübner, Jens-Martin (Author) , Camgöz, Aylin (Author) , Stainczyk, Sabine (Author) , Pfister, Stefan (Author) , Henrich, Kai-Oliver (Author) , Westermann, Frank (Author) , Kool, Marcel (Author)
Format:	Article (Journal)
Language:	English
Published:	June 10, 2021
In:	Journal of clinical oncology Year: 2021, Volume: 39, Issue: 29, Pages: 3217-3228
ISSN:	1527-7755
DOI:	10.1200/JCO.20.02540
Online Access:	Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.20.02540 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.20.02540
Author Notes:	Felix Schmitt-Hoffner, Sjoerd van Rijn, Umut H. Toprak, Monika Mauermann, Felix Rosemann, Anke Heit-Mondrzyk, Jens-Martin Hübner, Aylin Camgöz, Sabine Hartlieb, Stefan M. Pfister, Kai-Oliver Henrich, Frank Westermann, and Marcel Kool